

**SURGENE, GENEDIAB and GENESIS cohorts
including 1347 participants with type 1 diabetes
331 (26.8%) deaths**

Exclusion of participants without available data regarding:

- LLA at baseline (N= 35)**
- Vital status or follow-up data (N= 98)**

Exclusion of participants with PAD at baseline from:

- Group 1 (no CVD nor LLA) (N= 37)**
- Group 2 (CVD without LLA) (N=8)**

**Evaluation of 1169 participants
304 (26.0%) deaths during a median follow-up of 17 years**